Citigroup’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-39,222
| Closed | -$446K | – | 5960 |
|
|
2023
Q4 | $446K | Buy |
+39,222
| New | +$308K | ﹤0.01% | 3486 |
|
|
2023
Q1 | – | Sell |
-4
| Closed | -$28 | – | 5985 |
|
|
2022
Q4 | $28 | Sell |
4
-39
| -91% | -$329 | ﹤0.01% | 5689 |
|
|
2022
Q3 | $0 | Sell |
43
-29
| -40% | -$541 | ﹤0.01% | 6516 |
|
|
2022
Q2 | $1K | Sell |
72
-66
| -48% | -$1.71K | ﹤0.01% | 6143 |
|
|
2022
Q1 | $7K | Sell |
138
-437
| -76% | -$22.6K | ﹤0.01% | 5716 |
|
|
2021
Q4 | $43K | Buy |
575
+193
| +51% | +$13.2K | ﹤0.01% | 5142 |
|
|
2021
Q3 | $30K | Sell |
382
-10,085
| -96% | -$1.01M | ﹤0.01% | 5039 |
|
|
2021
Q2 | $1.45M | Buy |
10,467
+9,166
| +705% | +$1.75M | ﹤0.01% | 2936 |
|
|
2021
Q1 | $272K | Buy |
1,301
+102
| +9% | +$20.4K | ﹤0.01% | 3834 |
|
|
2020
Q4 | $199K | Buy |
1,199
+288
| +32% | +$44.5K | ﹤0.01% | 4994 |
|
|
2020
Q3 | $155K | Buy |
911
+600
| +193% | +$86.5K | ﹤0.01% | 4798 |
|
|
2020
Q2 | $52K | Sell |
311
-72
| -19% | -$11.2K | ﹤0.01% | 6001 |
|
|
2020
Q1 | $44K | Buy |
383
+36
| +10% | +$5.06K | ﹤0.01% | 6094 |
|
|
2019
Q4 | $51K | Buy |
347
+167
| +93% | +$25.3K | ﹤0.01% | 6298 |
|
|
2019
Q3 | $25K | Buy |
180
+23
| +15% | +$3.23K | ﹤0.01% | 6593 |
|
|
2019
Q2 | $20K | Buy |
157
+89
| +131% | +$10.3K | ﹤0.01% | 7095 |
|
|
2019
Q1 | $6K | Buy |
+68
| New | +$8.94K | ﹤0.01% | 7396 |
|
Citigroup's HARP Position: Q1 2024 in Review
Citigroup sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 39,222 shares — an estimated $446K sold.
Citigroup first reported a position in HARP in Q1 2019 and held it in 17 quarters. The position peaked at $1.45M in Q2 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Citigroup reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Citigroup sold 39,222 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $446K.
- Citigroup first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- Citigroup's Harpoon Therapeutics, Inc. Common Stock position peaked at $1.45M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.